Drugplain

Mycapssa 20 mg/1

Octreotide · CAPSULE, DELAYED RELEASE · Chiesi USA, Inc.

No Recall History
Plain English

Mycapssa is an oral capsule form of octreotide, a somatostatin analog used to treat acromegaly and neuroendocrine tumors. It works by reducing the production of certain hormones in the body and comes in a delayed-release formulation to help maintain consistent medication levels.

Key Facts

Brand Name
Mycapssa
Generic Name
Octreotide
NDC Code (Product)
10122-550
Manufacturer
Chiesi USA, Inc.
Strength
20 mg/1
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Marketing Status
Application #
NDA208232
Drug Class
Somatostatin Analog [EPC]
Marketing Start
07/06/2020

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

off label use700 reports
drug ineffective683 reports
diarrhoea543 reports
death380 reports
nausea367 reports
fatigue316 reports
malignant neoplasm progression243 reports
abdominal pain228 reports
vomiting215 reports
drug ineffective for unapproved indication186 reports

Frequently Asked Questions

What is Mycapssa used for?

Mycapssa is an oral capsule form of octreotide, a somatostatin analog used to treat acromegaly and neuroendocrine tumors. It works by reducing the production of certain hormones in the body and comes in a delayed-release formulation to help maintain consistent medication levels.

Is Mycapssa a controlled substance?

Mycapssa is not classified as a controlled substance by the DEA.

What is the generic name for Mycapssa?

The generic name for Mycapssa is Octreotide. There are 11 other brand versions of Octreotide.

What is the NDC code for Mycapssa 20 mg/1?

The NDC (National Drug Code) for Mycapssa 20 mg/1 is 10122-550, listed by Chiesi USA, Inc..

Product NDC

10122-550

Package NDC

10122-550-28

Other Octreotide Brands

See all →

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)